Labiotech.eu

Take a look at the Eli Lilly pipeline in 2026 as the incretin franchise grows and fuels the rest of the company's pipeline. The post Eli Lilly’s pipeline in 2026: how the incretin boom is funding what comes next appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/o…

Discover how early optimization in stable cell line development accelerates timelines and reduces downstream bottlenecks. The post Streamlining stable cell line development from the start appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly proh…

Discover Andy Brown's long and arduous journey battling a type of non-Hodgkin lymphoma and how a clinical trial altered his treatment outlook. The post When every treatment counts: How clinical trials are changing the outlook for non-Hodgkin lymphoma patients appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and …

Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and metabolic disease. The post Top biotech deals in August 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. …

Bladder cancer is the 10th most common cancer. Delve into the most promising strides in bladder cancer treatment. The post Bladder cancer treatment: where are we standing in 2026? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. …

The companies Moderna, Amylyx Pharmaceuticals, and Braveheart Bio bagged the biggest biotech funding rounds overall in August 2026. The post The biggest biotech funding rounds in August 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly p…

Find out what came out of the ESC Congress 2026, from phase 3 successes and failures to earlier-stage programs. The post ESC 2026: The drug development readouts that stood out appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Exce…

See why investor confidence in cell and gene therapies now depends on execution and supply chain strategy—not strong science alone. The post Investor confidence is built beyond the data appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohib…

The concept of targeted therapeutics is often traced back to German Nobel laureate Paul Ehrlich’s “magic bullet” in 1907, which envisioned a single entity that could both recognize a disease target and deliver a therapeutic effect specifically to it. This vision laid the conceptual foundation for modern conjugate drugs that followed.  The first major success in […] The post How AOCs are advancing…

Discover six MASH companies to keep an eye on as the race to shape the next generation of liver disease therapies heats up. The post Six MASH biotech companies shaping the future of liver disease treatment appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owne…

Saudi Arabia is pairing gene editing breakthroughs with new biomanufacturing capacity, from CRISPR oncology therapies to CDMOs like Lifera, as it builds a full biotech pipeline. The post Genomes to bioreactors: Saudi Arabia’s gene editing oncology push appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written…

In this article, we take a look at the various treatments in development to address the unmet needs of people with Charcot–Marie–Tooth disease. The post Charcot-Marie-Tooth disease: can medicines make it past clinical trials? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’…

Delve into the Sanofi pipeline strategy in 2026 after the company faced a few setbacks and made changes in leadership. The post Sanofi pipeline 2026: new leadership, same strategy? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited.…

Discover how small adjustments make your microbial process more robust and reproducible during scale-up and technology transfer. The post Could your microbial process be stronger? Uncovering opportunities before scale-up and commercialization appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permissio…

Amylin analogs are in clinical trials to address metabolic diseases on their own as well as to enhance the effects of GLP-1 drugs. The post Amylin analogs in the clinic: a deep dive appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited…

In recent years, biopharma has paid significantly different prices for the same underlying technology. In March 2025, AstraZeneca agreed to pay EsoBiotec, an in vivo CAR-T platform with early single-patient data, $425 million upfront and up to $575 million more in milestones. In August 2025, Gilead’s Kite paid $350 million for Interius BioTherapeutics, another in vivo CAR-T platform, also lentivi…

What if the key to beating cancer was a new way of thinking about matter? That's the question Laurent Lévy asked when he co-founded Nanobiotix over twenty years ago The post Beyond biology: Nanobiotix’s physics-first approach to cancer appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from …

Geneva’s life science industry is bound to western Switzerland's Health Valley ecosystem but is also growing in and of itself. The post Life science industry in Geneva on a roll appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Ex…